SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla informs about company updates

20 Jan 2020 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the Company from November 4, 2019 to November 13, 2019, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection. 

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1361.15 27.60 (2.07%)
06-May-2026 12:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1844.90
Dr. Reddys Lab 1294.90
Cipla 1361.15
Zydus Lifesciences 935.00
Lupin 2425.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×